Apellis Pharmaceuticals, Inc.
pegcetacoplan
focal segmental glomerulosclerosis (FSGS) and delayed graft function (DGF)
Date
TBD
Phase 2 readout · Date TBD estimated
What's at stake
Phase 2 trial results for pegcetacoplan in focal segmental glomerulosclerosis (FSGS) and delayed graft function (DGF) are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 15h ago
“initiated pivotal trials of EMPAVELI in focal segmental glomerulosclerosis (FSGS) and delayed graft function (DGF), two rare kidney diseases with significant complement pathway involvement and high unmet need.”